Subdural hematomas during CML therapy with imatinib mesylate

Leukemia and Lymphoma

Volumn 45, Issue 8, 2004, Pages 1633-1636

  Song, K W ^a   Rifkind, J ^a   Al Beirouti, B ^a   Yee, K ^a   McCrae, J ^a   Messner, H A ^a   Keating, A ^a   Lipton, Jeff H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic myeloid leukemia; Imatinib mesylate; Leukocytosis; Subdural hematoma; Thrombocytopenia

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; IMATINIB;

ADULT; ADVANCED CANCER; AGED; ARTHRITIS; ARTICLE; BRAIN HEMORRHAGE; CANCER GROWTH; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DEATH; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; FEMALE; HEADACHE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBDURAL HEMATOMA; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTINEOPLASTIC AGENTS; BLAST CRISIS; FEMALE; HEMATOMA, SUBDURAL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTOSIS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; RISK FACTORS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 3042731976     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001615666     Document Type: Article

References (13)

1. Sawyers, C.L. (1999) "Medical Progress: Chronic Myeloid Leukemia", New England Journal of Medicine, 340, 1330-1340.
2. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., et al. (2002) "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", New England Journal of Medicine, 346, 645-652.
3. Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., et al. (2002) "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study", Blood, 99, 1928-1937.
4. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., et al., (2001) "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome", New England Journal of Medicine, 344, 1038-1042.
5. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", New England Journal of Medicine, 344, 1031-1037.
6. Ebnether, M., Stentoft, J., Ford, J., Buhl, L. and Gratwohl, A. (2002) "Cerebral oedema as a possible complication of treatment with imatinib [letter]", Lancet, 359, 1751-1752.
7. Elliott, M.A., Mesa, R.A., Tefferi, A., Burton, C., Azzi, A. and Kerridge, I. (2002) "Adverse events after imatinib mesylate therapy", New England Journal of Medicine, 346, 712-713.
8. Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., et al. (2002) "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study", Blood, 99, 3530-3539.
9. Kantarjian, H.M., Dixon, D., Keating, M.J., Talpaz, M., Walters, R.S., McCredie, K.B., et al. (1988) "Characteristics of accelerated disease in chronic myelogenous leukemia", Cancer, 61, 1441-1446.
10. Druker, B.J., Sawyers, C.L., Capdeville, R., Ford, J.M., Baccarani, M. and Goldman, J.M. (2001) "Chronic myelogenous leukemia", Hematology (American Society of Hematology Educational Program), 87-112.
11. Yamauchi, K. and Umeda, Y. (1997) "Symptomatic intracranial haemorrhage in acute nonlymphoblastic leukaemia: analysis of CT and autopsy findings", Journal of Neurology, 244, 94-100.
12. Chen, J.C. and Levy, M.L. (2000) "Causes, epidemiology, and risk factors of chronic subdural hematoma". Neurosurgery Clinics of North America, 11, 399-406.
13. Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., et al. (2002) "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stomal tumors", NEJM, 347, 473-480.